Kyntra Bio (KYNB) Current Assets (2014 - 2026)
Kyntra Bio (KYNB) posted Current Assets of $101.4 million for Q1 2026, up 2.3% sequentially from $99.1 million in Q4 2025, and down 31.76% YoY from $148.5 million in Q1 2025.
Kyntra Bio (KYNB) Current Assets (2014 - 2026) Analysis & Trends
Kyntra Bio has reported Current Assets for 13 years, with the latest figure at $101.4 million in Q1 2026.
- Quarterly Current Assets fell 31.76% year-over-year to $101.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $101.4 million (down 31.76% YoY) and the FY2025 annual result came in at $99.1 million, down 49.58% from the prior year.
- Current Assets improved to $101.4 million in Q1 2026 per KYNB's latest filing, from $99.1 million in the prior quarter.
- Over five years, Current Assets peaked at $524.4 million in Q1 2022 and troughed at $99.1 million in Q4 2025.
- A 5-year average of $301.4 million and a median of $278.2 million in 2024 frame the typical range for Current Assets.
- The sharpest annual moves came in 2022 and 2025: Current Assets advanced 3.96% in 2022, then tumbled 49.58% in 2025.
- Over 5 years, Current Assets stood at $492.8 million in 2022, then sank by 32.72% to $331.6 million in 2023, then sank by 40.73% to $196.5 million in 2024, then sank by 49.58% to $99.1 million in 2025, then gained by 2.3% to $101.4 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $101.4 million, $99.1 million, and $133.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.14 Bn | 132.29 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 87.02 Bn | 79.03 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.12 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 60.84 Bn | 55.70 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.06 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.49 Bn | 28.18 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.78 Bn | 10.38 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.14 Bn | 26.31 Bn | - | 1.76 Bn |
| 10 | Kyntra Bio | 29.96 Mn | 29.96 Mn | 1.47 Mn | 96.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 96.83 Mn |
| Mar 31, 2026 | 101.36 Mn |
| Dec 31, 2025 | 99.07 Mn |
| Sep 30, 2025 | 133.42 Mn |
| Jun 30, 2025 | 162.32 Mn |
| Mar 31, 2025 | 148.53 Mn |
| Dec 31, 2024 | 196.51 Mn |
| Sep 30, 2024 | 244.53 Mn |
| Jun 30, 2024 | 209.46 Mn |
| Mar 31, 2024 | 278.17 Mn |
| Dec 31, 2023 | 331.56 Mn |
| Sep 30, 2023 | 364.11 Mn |
| Jun 30, 2023 | 411.36 Mn |
| Mar 31, 2023 | 430.55 Mn |
| Dec 31, 2022 | 492.83 Mn |
| Sep 30, 2022 | 474.22 Mn |
| Jun 30, 2022 | 520.64 Mn |
| Mar 31, 2022 | 524.42 Mn |
| Dec 31, 2021 | 474.06 Mn |
| Sep 30, 2021 | 573.40 Mn |